Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

Frank C. Odds, Mary Motyl, Roberto Andrade, Jacques Bille, Emilia Cantón, Manuel Cuenca-Estrella, Amanda Davidson, Christian Durussel, David Ellis, Elyse Foraker, Annette W. Fothergill, Mahmoud A. Ghannoum, Robert A. Giacobbe, Miguel Gobernado, Rosemary Handke, Michel Laverdière, Wendy Lee-Yang, William G. Merz, Luis Ostrosky-Zeichner, Javier Pemán & 12 others Sophia Perea, John R. Perfect, Michael A. Pfaller, Laurie Proia, John H. Rex, Michael G. Rinaldi, Juan Luis Rodriguez-Tudela, Wiley A. Schell, Christine Shields, Deanna A. Sutton, Paul E. Verweij, David W. Warnock

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode ± one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

Original languageEnglish (US)
Pages (from-to)3475-3482
Number of pages8
JournalJournal of Clinical Microbiology
Volume42
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

caspofungin
Aspergillus
Candida
Growth
Anti-Bacterial Agents
Itraconazole
Fluconazole
Quality Control
Glucose

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. / Odds, Frank C.; Motyl, Mary; Andrade, Roberto; Bille, Jacques; Cantón, Emilia; Cuenca-Estrella, Manuel; Davidson, Amanda; Durussel, Christian; Ellis, David; Foraker, Elyse; Fothergill, Annette W.; Ghannoum, Mahmoud A.; Giacobbe, Robert A.; Gobernado, Miguel; Handke, Rosemary; Laverdière, Michel; Lee-Yang, Wendy; Merz, William G.; Ostrosky-Zeichner, Luis; Pemán, Javier; Perea, Sophia; Perfect, John R.; Pfaller, Michael A.; Proia, Laurie; Rex, John H.; Rinaldi, Michael G.; Rodriguez-Tudela, Juan Luis; Schell, Wiley A.; Shields, Christine; Sutton, Deanna A.; Verweij, Paul E.; Warnock, David W.

In: Journal of Clinical Microbiology, Vol. 42, No. 8, 08.2004, p. 3475-3482.

Research output: Contribution to journalArticle

Odds, FC, Motyl, M, Andrade, R, Bille, J, Cantón, E, Cuenca-Estrella, M, Davidson, A, Durussel, C, Ellis, D, Foraker, E, Fothergill, AW, Ghannoum, MA, Giacobbe, RA, Gobernado, M, Handke, R, Laverdière, M, Lee-Yang, W, Merz, WG, Ostrosky-Zeichner, L, Pemán, J, Perea, S, Perfect, JR, Pfaller, MA, Proia, L, Rex, JH, Rinaldi, MG, Rodriguez-Tudela, JL, Schell, WA, Shields, C, Sutton, DA, Verweij, PE & Warnock, DW 2004, 'Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species', Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3475-3482. https://doi.org/10.1128/JCM.42.8.3475-3482.2004
Odds, Frank C. ; Motyl, Mary ; Andrade, Roberto ; Bille, Jacques ; Cantón, Emilia ; Cuenca-Estrella, Manuel ; Davidson, Amanda ; Durussel, Christian ; Ellis, David ; Foraker, Elyse ; Fothergill, Annette W. ; Ghannoum, Mahmoud A. ; Giacobbe, Robert A. ; Gobernado, Miguel ; Handke, Rosemary ; Laverdière, Michel ; Lee-Yang, Wendy ; Merz, William G. ; Ostrosky-Zeichner, Luis ; Pemán, Javier ; Perea, Sophia ; Perfect, John R. ; Pfaller, Michael A. ; Proia, Laurie ; Rex, John H. ; Rinaldi, Michael G. ; Rodriguez-Tudela, Juan Luis ; Schell, Wiley A. ; Shields, Christine ; Sutton, Deanna A. ; Verweij, Paul E. ; Warnock, David W. / Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. In: Journal of Clinical Microbiology. 2004 ; Vol. 42, No. 8. pp. 3475-3482.
@article{ba2ad12c4adc4bb5b0cbd6b5d3215e3c,
title = "Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species",
abstract = "Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual {"}prominent growth reduction{"} (MIC2) end points measured at 24 h in RPMI 1640, where 73.3{\%} of results for the 30 isolates tested fell within a mode ± one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.",
author = "Odds, {Frank C.} and Mary Motyl and Roberto Andrade and Jacques Bille and Emilia Cant{\'o}n and Manuel Cuenca-Estrella and Amanda Davidson and Christian Durussel and David Ellis and Elyse Foraker and Fothergill, {Annette W.} and Ghannoum, {Mahmoud A.} and Giacobbe, {Robert A.} and Miguel Gobernado and Rosemary Handke and Michel Laverdi{\`e}re and Wendy Lee-Yang and Merz, {William G.} and Luis Ostrosky-Zeichner and Javier Pem{\'a}n and Sophia Perea and Perfect, {John R.} and Pfaller, {Michael A.} and Laurie Proia and Rex, {John H.} and Rinaldi, {Michael G.} and Rodriguez-Tudela, {Juan Luis} and Schell, {Wiley A.} and Christine Shields and Sutton, {Deanna A.} and Verweij, {Paul E.} and Warnock, {David W.}",
year = "2004",
month = "8",
doi = "10.1128/JCM.42.8.3475-3482.2004",
language = "English (US)",
volume = "42",
pages = "3475--3482",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

AU - Odds, Frank C.

AU - Motyl, Mary

AU - Andrade, Roberto

AU - Bille, Jacques

AU - Cantón, Emilia

AU - Cuenca-Estrella, Manuel

AU - Davidson, Amanda

AU - Durussel, Christian

AU - Ellis, David

AU - Foraker, Elyse

AU - Fothergill, Annette W.

AU - Ghannoum, Mahmoud A.

AU - Giacobbe, Robert A.

AU - Gobernado, Miguel

AU - Handke, Rosemary

AU - Laverdière, Michel

AU - Lee-Yang, Wendy

AU - Merz, William G.

AU - Ostrosky-Zeichner, Luis

AU - Pemán, Javier

AU - Perea, Sophia

AU - Perfect, John R.

AU - Pfaller, Michael A.

AU - Proia, Laurie

AU - Rex, John H.

AU - Rinaldi, Michael G.

AU - Rodriguez-Tudela, Juan Luis

AU - Schell, Wiley A.

AU - Shields, Christine

AU - Sutton, Deanna A.

AU - Verweij, Paul E.

AU - Warnock, David W.

PY - 2004/8

Y1 - 2004/8

N2 - Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode ± one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

AB - Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode ± one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

UR - http://www.scopus.com/inward/record.url?scp=3843088493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3843088493&partnerID=8YFLogxK

U2 - 10.1128/JCM.42.8.3475-3482.2004

DO - 10.1128/JCM.42.8.3475-3482.2004

M3 - Article

VL - 42

SP - 3475

EP - 3482

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 8

ER -